Search company, investor...
TxCell company logo


Founded Year



Take Private | Alive

Total Raised


About TxCell

TxCell is dedicated to the development of therapeutic products for severe chronic inflammatory and autoimmune diseases with hight unmet medical need including inflammatory bowel diseases, inflammatory joint diseases and neurological diseases such as Multiple Sclerosis. The product candidates developed by TxCell consist of antigen-specific Type 1 regulatory cells (Ag-Tregs) generated ex-vivo from patient's peripheral blood in a proprietary manufacturing process (link). The company's lead product candidate, Ovasave, has completed a PI/II clinical trial in Crohn's disease patients, refractory to all current treatments.

Headquarters Location

Allée de la Nertière

Valbonne, 06560,


+33(0) 497 218 300

Missing: TxCell's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: TxCell's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing TxCell

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

TxCell is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

TxCell Patents

TxCell has filed 1 patent.

The 3 most popular patent topics include:

  • Autoimmune diseases
  • Designer drugs
  • Immunology
patents chart

Application Date

Grant Date


Related Topics




Immunology, Autoimmune diseases, Immune system, Clusters of differentiation, Rare diseases


Application Date


Grant Date



Related Topics

Immunology, Autoimmune diseases, Immune system, Clusters of differentiation, Rare diseases



Latest TxCell News

SparingVision raises €44.5M to develop mutation-agnostic gene therapy

Oct 21, 2020

SparingVision CEO Stéphane Boissel (TxCell) SparingVision has raised €44.5 million ($52.5 million) to develop its mutation-agnostic gene therapy treatment for retinitis pigmentosa (RP). The financing positions SparingVision to fund clinical trials of an AAV gene therapy that could stop vision deterioration in the 2 million RP patients. Gene therapies including Roche’s Luxturna are designed to address genetic drivers that cause some patients to develop RP and suffer vision loss. However, with at least 65 distinct RP-causing mutations of three different types, the numbers of patients that can be helped with any one gene-replacement therapy are relatively small. SparingVision, in contrast, is going after the whole RP market. “It’s gene therapy but it’s mutation agnostic. The market potential is very large, unlike most gene therapies being developed, which address very specific mutations [in the eye]. The commercial viability of those mutation-specific gene therapies is kind of questionable,” Stéphane Boissel, who recently took over as CEO of SparingVision, said. Webinar Digitize remote site monitoring with Box Box will discuss how your life sciences organization can continue to propel therapies & devices through the value chain with faster and even more secure site monitoring and auditing. The mutation-agnostic approach is built on an understanding of RP. The deterioration of the vision of RP patients begins with the degeneration of rod photoreceptors. That causes night blindness. Over time, cone photoreceptors start to degenerate, causing vision to deteriorate to the point that a patient is legally blind, despite most known genetic mutations only affecting the rods. SparingVision’s scientific founders identified an explanation for the loss of cones. As the number of rods falls, cones receive lower levels of the neurotrophic factors released by the photoreceptors. The loss of rods leads to lower levels of the neurotrophic factors, which in turn causes the loss of cones. The research led to a novel gene therapy approach. Unlike treatments such as Luxturna, the gene therapy does not seek to replace a faulty or missing gene. Rather, the therapy is designed to ensure cones have access to the molecules that support their preservation. The gene therapy encodes for neutrophil factor RdCVF and an enzyme, potentially enabling it to restore aerobic glycolysis in cones and protect them from oxidative stress. “The idea is not to restore vision. The idea is to slow or stop the progression of the disease by preventing the cones from further degenerating,” Boissel said. SparingVision has raised €44.5 million to pursue that idea, bringing its total series A financing haul up to around €60 million. With GMP manufacturing almost done and IND-enabling studies underway, the money will enable SparingVision to move into a clinical trial to assess the safety of its candidate next year. Once SparingVision has safety data, it will run an efficacy trial using the series A funds. The potential to take a mutation-agnostic RP gene therapy to clinical proof of concept has attracted a diverse group of investors. Advanced therapy VC 4BIO Capital led the round with UPMC Enterprises, the venture arm of healthcare provider and insurer UPMC. Jeito Capital, Ysios Capital, Bpifrance and Foundation Fighting Blindness—a charity that funded research into RdCVF—also participated. “The syndicate that we put together is not the typical VC syndicate. This is a well-balanced group of typical VCs but also very long-term, patient-centric investors. We have no pressure to, for example, exit. The only pressure we have is to deliver a drug to the patients,” Boissel said. Boissel has taken up that challenge after two years at Sangamo Therapeutics, which bought the last company he led, TxCell, for €72 million. The CEO is now building out the rest of the team, with a chief technical officer set to join soon and a chief medical officer slated to arrive in the new year. The team will work to advance the lead candidate into the clinic and expand into the U.S. Read more on

TxCell Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

TxCell Rank

TxCell Frequently Asked Questions (FAQ)

  • When was TxCell founded?

    TxCell was founded in 2001.

  • Where is TxCell's headquarters?

    TxCell's headquarters is located at Allée de la Nertière, Valbonne.

  • What is TxCell's latest funding round?

    TxCell's latest funding round is Take Private.

  • How much did TxCell raise?

    TxCell raised a total of $32M.

  • Who are the investors of TxCell?

    Investors of TxCell include Sangamo Therapeutics, Seventure Partners, Auriga, Innovation Capital, InnoBio and 5 more.

  • Who are TxCell's competitors?

    Competitors of TxCell include Quell Therapeutics, CVRx, Intarcia Therapeutics, Intercept Pharmaceuticals, GlobeImmune and 9 more.

Compare TxCell to Competitors

Actinobac Biomed

Actinobac Biomed is a biopharmaceutical company developing therapeutics for multiple indications, including blood cancers, autoimmune/inflammatory diseases, and HIV. Its drug candidates are based upon Leukothera (LtxA), a natural protein that targets and eliminates white blood cells (WBCs) involved in the mechanism of many diseases. Products based upon Leukothera are being developed by Actinobac for the treatment of leukemia/lymphoma, dry eye, and psoriasis.


Asterion is a manufacturer of analog semiconductors.


NovoCell, Inc./BresaGen is a stem cell engineering company dedicated to creating, delivering, and commercializing cell and drug therapies to treat diabetes and other chronic diseases. Novocell uses its cell encapsulation technology and expertise in cell implantation to develop a renewable source of specialized cells for the treatment of cellular diseases. Bresagen represents a division of Novocell's research operation.

Traversa Therapeutics

Traversa Therapeutics is a biopharmaceutical company engaged in the discovery, development and commercialization of RNAi anti-cancer therapeutics. The company strives to rapidly advance short interfering RNA (siRNA) platform delivery technologies for use by RNAi therapeutic companies in targeting a variety of acute, chronic and infectious human diseases. Traversa is focused on the optimization of platform delivery technology, as well as advancement of therapeutic programs for the treatment of leukemia and glioblastoma.

Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

CoImmune Logo

CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.